Viral epidemics and pandemics
Outcomes
We help assay developers and clinical labs respond to outbreaks like coronavirus, Ebola and Zika. Our AccuPlex recombinant viral materials are safe to handle and non-infectious, while resembling complex clinical virus targets, making them a crucial tool in developing effective solutions to fight infectious disease epidemics like COVID-19.
LGC's response to the COVID-19 PandemicFood safety city
Outcomes
LGC provides proficiency testing schemes to help monitor the quality and accuracy of the testing which is carried out in Xiamen, one of the largest food and drink export hubs in the world.
Innovation in nucleic acid therapies
Outcomes
Through our nucleic acid chemistry capabilities, we enable healthcare professionals to develop new therapies, which transform the quality of life for patients. Our oligo components, probes and primers enable detection and development of vaccines for illnesses like COVID-19.
Improving farming productivity
Outcomes
We partner with agricultural biotechnology companies to solve the productivity challenge that sits at the heart of the global food supply problem. Our range of products and services help accelerate breeding decisions in an efficient and cost-effective manner, such as identifying new plant varieties.
Bioanalysis in pharmaceuticals
Outcomes
With our extensive capabilities in mass spectrometry and immunoassay, LGC plays a critical role in launching new treatments for illnesses such as cancer, heart disease, diabetes and asthma, ultimately helping to improve the quality of people’s lives.